Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

224
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
224
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
Pharmacovigilance01:19

Pharmacovigilance

773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and Clinical Impact of Pathogenic Variants in Cardiomyopathy Genes Among Individuals with Cardiac Conduction Disorders.

medRxiv : the preprint server for health sciences·2026
Same author

DRIVE v3: Command Line Application for Identity-by-Descent Haplotype Clustering in Large Biobank Scale Data.

Genetic epidemiology·2026
Same author

Correction to: Microvascular Function and Ambulatory Capacity in Peripheral Artery Disease.

Circulation. Cardiovascular interventions·2026
Same author

Proteogenomic Analysis of Coronary Artery Calcification in Human Populations.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Estradiol treatment induces both shared and unique gene regulation and networks in adipose cell types of gonadectomized obese XX and XY mice.

Biology of sex differences·2026
Same author

Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma.

Cancers·2026
Same journal

Prevalence of food addiction and its association with ghrelin and metabolic parameters in patients with type 1 diabetes mellitus: a cross-sectional study.

BMC endocrine disorders·2026
Same journal

Machine learning-assisted prediction of obstructive sleep apnea in patients with metabolic dysfunction-associated steatotic liver disease: a multicenter study with external validation.

BMC endocrine disorders·2026
Same journal

MCD biomarkers Egfr, Hmox1, Lgmn identified in NAFLD.

BMC endocrine disorders·2026
Same journal

Prognostic factors and prognostic risk score of 30-day all-cause mortality in thyroid storm.

BMC endocrine disorders·2026
Same journal

Barriers to glycemic control among youth with diabetes in Ghana: a mixed-methods cross-sectional study.

BMC endocrine disorders·2026
Same journal

Impact of growth hormone preparation switching on treatment outcomes in children with growth hormone deficiency: a retrospective real-world cohort study.

BMC endocrine disorders·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2025

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.4K

Predicting responsiveness to GLP-1 pathway drugs using real-world data.

Xiaodong Zhu1,2, Michael J Fowler2, Quinn S Wells2,3

  • 1Department of Veterans Affairs, Tennessee Valley Health Authority, Nashville, TN, USA.

BMC Endocrine Disorders
|December 19, 2024
PubMed
Summary
This summary is machine-generated.

A predictive model using electronic health records identifies patient subgroups most likely to benefit from glucagon-like peptide-1 (GLP-1) pathway medications for Type 2 diabetes. Higher pre-treatment HbA1C predicts better response, while certain other medications correlate with poorer outcomes.

Keywords:
Electronic health recordGLP-1HbA1cPredictive modelType 2 diabetes

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K

Related Experiment Videos

Last Updated: Jun 4, 2025

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.4K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K

Area of Science:

  • Diabetes Mellitus Research
  • Pharmacogenomics
  • Health Informatics

Background:

  • Glucagon-like peptide-1 (GLP-1) pathway medications are crucial for Type 2 diabetes (T2D) management.
  • Identifying patient subgroups that benefit most from GLP-1 medications remains a challenge.

Purpose of the Study:

  • To develop a predictive model for patient responsiveness to GLP-1 medications (GLP-1 receptor agonists and DPP4 inhibitors).
  • To guide clinicians in selecting second-line T2D treatments based on patient characteristics.

Main Methods:

  • Analysis of de-identified electronic health records from 7856 T2D patients (2003-2019).
  • Comparison of logistic regression, LightGBM, artificial neural network, and support vector classifier models.
  • Inclusion of clinical features, lab tests, demographics, and diabetes complications.

Main Results:

  • Logistic regression model achieved an auROC of 0.77, outperforming other machine learning models.
  • Higher pre-treatment HbA1C predicted better response to GLP-1 medications.
  • Use of thiazolidinediones or sulfonylureas correlated with poorer response.
  • In female patients under 40, NSAID use was associated with greater HbA1C reduction.

Conclusions:

  • Real-world data analysis can refine T2D treatment decisions.
  • The predictive model emphasizes individual patient characteristics and drug interactions for optimizing GLP-1 medication prescribing.